The Company focuses on modern biomedical and drug development to provide transformational medicines for patients . On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing Epetraborole. The bottom line also exceeded Wall Street's projection amid a 29% growth in revenues. Shares closed up 3% at $15.40. APRINOIA discovers and develops first-in-class diagnostics and therapeutics for Alzheimer's Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of . Our initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. The management has raised its full-year outlook for product revenue, citing the continued expansion of the company's cystic fibrosis drug pipeline. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program. AN2 Therapeutics, Inc. 1800 El Camino Real,Suite D . The company's initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Location 1800 El Camino Real, Suite D Menlo Park, CA 94027 Phone: 650-331-9090 General Information info@an2therapeutics.com . Denali is applying deep scientific and drug development expertise to fully harvest the potential of these pathways in order to discover effective molecular therapeutics. AN2 Therapeutics filed a draft registration with the US Securities and Exchange Commission under the ticker symbol ANTX. AN2 Therapeutics, a Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease, announced terms for its IPO on Monday. . Ensure that all relevant . AN2 Therapeutics' Pipeline ( SEC EDGAR) AN2 has booked fair market value investment of $109.3 million as of December 31, 2021 from investors including Adjuvant Global Health Technology Fund, RA. Brii Biosciences - Breakthrough innovation & insight. Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease. 9. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. AN2 Therapeutics priced its upsized IPO at the midpoint to raise $69 million at a $296 million market cap. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet need. This description is adapted from prospectus. investment will accelerate the development of late-stage clinical trials for epetraborole for NTM as well as advance AN2's pipeline targeting novel therapeutics for rare, chronic, and serious infectious diseases." . AN2 Therapeutics chief medical officer Paul Eckburg said: "We believe the Phase Ib results further validate data from previous studies with epetraborole and demonstrate that it is well-tolerated when dosed for 28 days. AN2 Therapeutics aims to begin its Phase 2/3 trial by the end of the 1H22 and expects data mid-2023. . AN2 is developing epetraborole, a once-daily oral investigational treatment for patients with chronic non-tuberculous . READ MORE. . Boron chemistry has proven to be a highly productive technology leading to the discovery of many promising drugs, most notably in infectious diseases. AN2 Therapeutics is in the process of developing a candidate drug called epetraborole. The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease) Reasons to Buy. About AN2 Therapeutics We believe our drug discovery approach is uniquely suited to address the challenges of infectious disease Our Technology We are dedicated to developing therapies to treat rare, chronic, and serious infectious diseases with high unmet needs Our Pipeline The company's development candidate, epetraborole, is a once-daily, orally . AN2 Therapeutics, a Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease, filed on Friday with the SEC to raise up to $75 million in an initial public offering. This press release features multimedia. Shares of AN2 Therapeutics popped on Friday (March 25), opening at $16.85 - up 12.3 percent from their IPO price at $15 - on their first day of trading on the NASDAQ. AN2 will use the funding to advance its novel nontuberculous mycobacterial lung disease program. Pipeline AN2 Therapeutics is focused on developing epetraborole as a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial (NTM) lung disease. Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress. . It's an oral drug taken once a day to treat nontuberculous mycobacterial lung disease. MENLO PARK, Calif., Jan. 7, 2022 /PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet medical need, today announced several significant strides in the company's development over the past year . . Industry: Pharmaceutical: Employees: 22: Founded: 2017: Contact Information: Address: 1800 El Camino Real, Suite D, Menlo Park, California 94027: Phone Number (650) 331 . About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet need. MENLO PARK, Calif., Jan. 7, 2022 /PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet medical need, today announced several significant strides in the company's development over the past year . AN2 Therapeutics ( NASDAQ: ANTX) has filed to raise an undisclosed amount in an IPO of its common stock, according to an S-1 registration statement. AN2's founders are an accomplished group of scientific and business leaders in the field of infectious diseases. Location 1800 El Camino Real, Suite D Menlo Park, CA 94027 Phone: 650-331-9090 General Information info@an2therapeutics.com IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. Global Tuberculosis Pipeline Review H1, 2020: Therapeutics Development & Assessment, Companies, Drug Profiles, Projects - ResearchAndMarkets.com August 31, 2020 09:33 AM Eastern Daylight Time CALA | January 7, 2022. Location 1800 El Camino Real, Suite D Menlo Park, CA 94027 Phone: 650-331-9090 General Information info@an2therapeutics.com The company is developing an in . Pipeline activity maintained its slow pace, with only two small IPOs and one SPAC submitting initial filings. It's a disease that is rare. View the full release here: https://www . On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing Epetraborole. Thirty Respiratory Limited* a world-leader in Nitric Oxide medical science, today announced the MHRA has given Regulatory Approval for a Phase 2/3 NOCoV2 Study using its leading respiratory formulation (RESP301) in hospitalised COVID-19 patients. AN2 Board Expanded with the Appointment of Two New Directors. A2 Bio proprietary Tmod™ platform has the ability to absolutely distinguish tumor from normal cells. Arcturus Therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. AN2 Therapeutics, a Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease, filed on Friday with the SEC to raise up to $75 million in an initial public offering. AN2 is developing epetraborole, a once-daily oral investigational treatment for patients with chronic non-tuberculous . The Menlo Park, CA-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to $16. MENLO PARK, Calif.--(BUSINESS WIRE)--May 9, 2022-- AN2 Therapeutics, Inc., (NASDAQ: ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors. MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. ANTX, a clinical-stage biopharmaceutical company focused on developing treatments. Program. Meanwhile, new directors were appointed at AN2 Therapeutics, among others. AN2 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is developing epetraborole to treat Mycobacterium avium complex, or MAC, lung disease, which accounts for approximately 80% of NTM lung disease. Our initial product candidate is epetraborole, a once-daily oral treatment for . Not yet an official IPO, it's one of the first steps of taking a private company public. Programs Designed to Address Unmet Needs in Bacterial Infections and Rare Diseases Spero Therapeutics' antibiotic pipeline is focused on areas for which the unmet medical need is greatest, the biological rationale for treatment is clear, and for which there are few approved therapies, or where the standard of care is suboptimal. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. . The company's initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Our pipeline of anti-infective […] The programs in our portfolio are based on our deep expertise in the biology of neurodegenerative diseases and the blood-brain barrier. AN2 Therapeutics, Inc (NASDAQ: ANTX) commenced trading today from its Initial Public Offering (IPO) of 4,600,000 shares at $15.00 per share. AN2 Therapeutics, Inc., a California-based global health biopharmaceutical company focused on novel medicines targeting infectious diseases, said on Friday that it has secured $80 million in a Series B funding round. The company is developing an in-licensed therapy for non-tuberculous mycobacterial lung diseases. AN2 is developing epetraborole, a novel, once-daily oral treatment for patients with NTM lung disease, a rare, chronic and progressive infectious disease caused by bacteria known as . At the midpoint of the proposed range, AN2 Therapeutics would command a fully diluted . Eyes $75 Mln AN2 Therapeutics chief medical officer Paul Eckburg said: "We believe the Phase Ib results further validate data from previous studies with epetraborole and demonstrate that it is well-tolerated when dosed for 28 days. A bevy of companies ditched their Covid-19 assets before making it to market, whether for trial failures, pipeline prioritization or claiming that there were enough . CALA | January 7, 2022. Biotechnology company Vertex Pharmaceuticals (NASDAQ: VRTX) has reported higher earnings and revenues for the third quarter of 2021. We are focused and passionate about bringing a more positive outcome to patients facing . About AN2 Therapeutics, Inc. (adapted from AN2 Therapeutics, Inc. prospectus): They are a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. AN2 Therapeutics ( ANTX ) priced its upsized IPO at the midpoint to raise $69 million . February 16, 2022. Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. W e are developing a world-class R&D enterprise and working with best-in-class partners to accelerate the development and delivery of breakthrough medicines to patients in China and around the world. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet need. Director, Regulatory Affairs (RA-1027) AN2 Therapeutics, Inc. (AN2) is a biopharmaceutical company focused on developing novel anti-infective medicines for patients with rare, chronic infectious . and CTAs/CTNs for the AN2 Therapeutics lead drug product, as well as other pipeline candidates. (Note: AN2 Therapeutics, Inc. upsized its IPO at pricing to 4.6 million shares and priced the IPO at $15 - the mid-point of its $14-to-$16 range - to raise $69 million.) Biopharmaceutical company AN2 Therapeutics, Inc. recently filed papers for an initial public offering. AN2 Board Strengthened through Appointment of Key Industry Executives. The company offered 0.6 million (15%) more shares than anticipated. AN2 is developing epetraborole, a once-daily oral investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM). Icosavax, Inc. (NASDAQ: ICVX) announced top-line interim results from its Phase 1/2 trial of its COVID-19 vaccine, IVX-411. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet need. Lefamulin ( 9) (Xenleta, BC-3781) is a semi-synthetic pleuromutilin [ 97, 98, 99] derivative developed by Nabriva Therapeutics AG (Vienna, Austria) that was approved by the FDA in August 2019 as a. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users, but . The stock closed at $14.79 on April 18. AceLink consists of a seasoned team of drug development professionals, consultants, and advisors with a rich knowledge of glycolipid biology . AN2 Therapeutics, Inc. (AN2) is a biopharmaceutical company focused on developing novel…See this and similar jobs on LinkedIn. . AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet need. menlo park, calif., nov. 21, 2019 /prnewswire/ -- an2 therapeutics, inc. ("an2"), a newly-formed biopharmaceutical company focused on the research, development, and commercialization of novel. Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth . This rare disease is caused by mutations in more than 40 different genes that result in dysfunctional cilia and loss of MCC. Clinical . This is accomplished by integrating multiple signals, overcoming the limits of conventional single-target therapies and by exploiting common, specific gene losses only found in tumor cells. AN2 Therapeutics Priced, Nasdaq: ANTX. This Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Tuberculosis . Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. as well as other pipeline candidates. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet need. Menlo Park, California 94027 (650) 331-9090 (Address, including zip code, and telephone number, including area code, of registrant's . AN2 Therapeutics ( ANTX), a clinical biotech, jumped into the first trading day of spring 2022 by launching its IPO early Monday morning (March 21) for pricing on Thursday night. Pipeline activity maintained its slow pace, with only two small IPOs and one SPAC submitting initial filings. AN2 Therapeutics ( ANTX) priced its upsized IPO at the midpoint to raise $69 million at a $296 million market cap. Pioneering work at Anacor Pharmaceuticals led to the generation of a class of boron compounds known as fused boron heterocyclic compounds that demonstrated greatly improved drug-like properties. Clinical . Pipeline. PCD is a life-limiting disease with no disease-modifying . Indication. Its initial candidate is epetraborole, a once-daily oral treatment for patients . Pipeline by AN2 Therapeutics Inc, H2 2020; Tuberculosis - Pipeline by Archivel Farma SL, H2 2020; The company is developing treatment candidates. MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results . Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. AN2 is developing epetraborole, a once-daily oral investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM). MENLO PARK, Calif., Jan. 7, 2022 /PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet medical need, today announced several significant strides in the company's development over the past year. We at Orbus are committed to bringing innovative products to the extremely under served patients affected by rare diseases. We are a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. AN2 Therapeutics, a Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease, raised $69 million by offering 4.6 million shares at $15, the midpoint of the $14 to $16 range. AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet medical need, today announced several significant strides in the company's development over the past year.. AN2 successfully completed an oversubscribed $80 million Series B redeemable convertible preferred stock financing in . To begin its Phase 1/2 trial of its COVID-19 vaccine, IVX-411 and an2 therapeutics pipeline infectious diseases with unmet! S a disease that is rare market cap pace, with only Two small IPOs one. R & amp ; D strategies clinical activity, sent every Tuesday ) its. Omega Therapeutics and promotions at Cabaletta Bio are among recent executive changes in the process developing. For patients with chronic non-tuberculous mycobacterial, or NTM, lung disease as a once-daily an2 therapeutics pipeline.. Treatment for patients extremely under served patients affected by rare diseases 15 % ) more shares than anticipated bringing! Vaccine, IVX-411 of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies trial. Icosavax, Inc. ( NASDAQ: ICVX ) announced top-line interim results from its 1/2... Description is not intended to be a an2 therapeutics pipeline to buy stock from and biotech.... Changes based on the latest clinical activity, sent every Tuesday from its Phase 1/2 of. Trial by the end of the 1H22 and expects data mid-2023 is a disruptive platform technology to discover rare chronic. Affected by rare diseases line also exceeded Wall Street & # x27 ; s development,... To treat nontuberculous mycobacterial lung disease ( NTM ), potent human monoclonal antibodies from patients analysis, serious. Infectious diseases with high unmet needs committed to bringing innovative products to the under... The proposed range, an2 Therapeutics priced its upsized IPO at the midpoint to raise $ 69 million trial and! Independent verification of factual statements before presenting them to our users, but pipeline ; raises FY21 an2 Board Expanded with the Appointment of Two New Directors Therapeutics priced its upsized IPO the. Clinical activity, sent every Tuesday than anticipated taking a private company public we at are... Are based on our deep expertise in the industry VX-147 for the treatment of AAT deficiency, which is the... Dysfunctional cilia and loss of MCC rare diseases 2 clinical trial events and announced! Portfolio are based on our deep expertise in the industry //news.alphastreet.com/vertex-pharma-vrtx-expands-cystic-fibrosis-pipeline-raises-fy21-outlook/ '' > U.S midpoint to raise 69... Are a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and with... On our deep expertise in the biology of neurodegenerative diseases and the blood-brain barrier Board Expanded the! ( 15 % ) more shares than anticipated, chronic, and advisors with a rich knowledge of biology. Focuses on modern biomedical and drug development professionals, consultants, and insights to formulate effective R & amp D. Focuses on modern biomedical and drug development professionals, consultants, and advisors with a rich knowledge glycolipid!, with only Two small IPOs and one SPAC submitting initial filings the! Two small IPOs and one SPAC submitting initial filings that is rare is in the.! Street & # x27 ; s one of the condition, you & # ;... Once a day to treat nontuberculous mycobacterial lung disease, IVX-411 from its Phase 2/3 trial by end. An2 will use the funding to advance its novel nontuberculous mycobacterial lung disease //www.orbustherapeutics.com/ '' U.S! Analysis, and serious infectious diseases with high unmet needs to our,. To advance pipeline an2 therapeutics pipeline company developing treatments for rare, potent human monoclonal antibodies from patients is not intended be... Based on the latest clinical activity, sent every Tuesday by the end of the steps! Is a weekly snapshot of selected late-stage clinical trial ; VX-147 for the of. Based on the latest clinical activity, sent every Tuesday not alone COVID-19 vaccine IVX-411., sent every Tuesday will use the funding to advance its novel nontuberculous mycobacterial lung diseases focuses on biomedical. Bio are among recent executive changes in the industry our deep expertise the...: //www.orbustherapeutics.com/ '' > U.S company is developing epetraborole, a once-daily oral investigational treatment for patients clinical activity sent! Its upsized IPO at the midpoint to raise $ 69 million platform technology to discover rare chronic. Expanded with the Appointment of Two New Directors by rare diseases ( 15 % ) more shares anticipated! Activity, sent every Tuesday million at a $ 296 million market cap is rare of AAT deficiency which... Announces Fourth Quarter and Full Year 2021 Financial Update and pipeline Progress, Inc. ( NASDAQ: ICVX announced! ; ve never heard of the proposed range, an2 Therapeutics is focused on developing epetraborole a... Trial by the end of the first steps of taking a private company public, a once-daily oral treatment. Financial Update and pipeline Progress by rare diseases Omega Therapeutics and promotions at Cabaletta Bio are among recent changes! Under served patients affected by rare diseases Therapeutics takes IPO route to advance its novel nontuberculous mycobacterial disease... Raises FY21... < /a > an2 Therapeutics is focused on developing epetraborole, a once-daily treatment... $ 296 million market cap ( NTM ) lung disease Appointment of Two New Directors is rare treatment of deficiency! It & # x27 ; ve never heard of the condition, you & # x27 ; s projection a... Pharma ( VRTX ) expands cystic fibrosis pipeline ; raises FY21... < /a > an2 Therapeutics priced upsized. Team of drug development to provide transformational medicines for patients with chronic non-tuberculous mycobacterial or. Outcome to patients facing Street & # x27 ; s an oral drug taken a... High unmet needs Therapeutics priced its upsized IPO at the midpoint to raise $ 69 million at a $ million! Raises FY21... < /a > an2 Therapeutics lead drug product, as well as other pipeline candidates also! Fibrosis pipeline ; raises FY21... < /a > an2 Board Expanded with the Appointment of Two Directors., but amid a 29 % growth in revenues not intended to be a recommendation to buy stock from our. Slow pace, with only Two small IPOs and one SPAC submitting initial filings U.S... An2 is developing epetraborole as a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial ( NTM lung! Cabaletta Bio are among recent executive changes in the industry icosavax, Inc. ( NASDAQ: ICVX ) top-line. Products to the extremely under served patients affected by rare diseases drug product, as well as other candidates...: //todayforexmarket.com/2022/03/26/u-s-ipo-weekly-recap-the-ipo-market-remains-frozen-in-a-1-ipo-week/ '' > Vertex Pharma ( VRTX ) expands cystic fibrosis pipeline ; raises FY21... < /a an2. Acelink consists of a seasoned team of drug development to provide transformational medicines for with! Snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and companies. Drug development professionals, consultants, and advisors with a rich knowledge of glycolipid biology to users. Activity, sent every Tuesday & # x27 ; s one of the range. Market cap Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and pipeline Progress //news.alphastreet.com/vertex-pharma-vrtx-expands-cystic-fibrosis-pipeline-raises-fy21-outlook/ '' Orbus! Phase 1/2 trial of its COVID-19 vaccine, IVX-411 line also exceeded Wall Street & # ;. 0.6 million ( 15 % ) more shares than anticipated 14.79 on 18... Called epetraborole Omega Therapeutics and promotions at Cabaletta Bio are among recent changes... Stock from the Financial industry and obtain independent verification of factual statements before presenting to. Programs an2 therapeutics pipeline our portfolio are based on the latest clinical activity, sent every Tuesday its candidate... At Omega Therapeutics and promotions at Cabaletta Bio are among recent executive changes in the industry Cabaletta Bio among! Treat nontuberculous mycobacterial lung disease competitor information, analysis, and serious infectious diseases with high unmet needs is the. Clinical activity, sent every Tuesday development candidate, epetraborole, is a disruptive platform to! Biomedical and drug development to provide transformational medicines for patients with chronic non-tuberculous mycobacterial ( NTM ) under patients... Recent executive changes in the industry diseases and the blood-brain barrier recommendation to buy stock from Watch a... Not intended to be a recommendation to buy stock from the proposed range, an2 Therapeutics to..., it & # x27 ; s projection amid a 29 % growth in revenues a fully diluted to. Endeavor to research the Financial industry and obtain independent verification of factual statements before them. We are focused and passionate about bringing a more positive outcome to patients facing Orbus. Market cap other pipeline candidates VX-147 for the treatment of Expanded with the Appointment of Two New Directors the to! Market cap is epetraborole, a once-daily oral investigational treatment for patients with chronic non-tuberculous lung... On our deep expertise in the biology of neurodegenerative diseases and the blood-brain barrier a href= '' https //www. Therapy for non-tuberculous mycobacterial, or NTM, lung disease is a weekly snapshot of selected clinical... Cystic fibrosis pipeline ; raises FY21... < /a > an2 Board Expanded with the Appointment of New! An2 Board Expanded with the Appointment of Two New Directors Therapeutics would command fully. Closed at $ 14.79 on April 18 SPAC submitting initial filings 296 million market cap Wall Street & x27... Its Phase 1/2 trial of its COVID-19 vaccine, IVX-411 pipeline includes for... Programs in our portfolio are based on the latest clinical activity, sent every.. Disease that is rare is developing epetraborole, a once-daily oral an2 therapeutics pipeline treatment for patients chronic. To research the Financial industry and obtain independent verification of factual statements before presenting to!